Compile Data Set for Download or QSAR
Report error Found 146 Enz. Inhib. hit(s) with all data for entry = 1277
TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283463BDBM283463(US10023557, Example 115 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283462BDBM283462(US10023557, Example 114 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283465BDBM283465(US10023557, Example 117 | N-((6-amino-2-methylpyri...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283464BDBM283464(US10023557, Example 116 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283467BDBM283467(US10023557, Example 119 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283466BDBM283466(US10023557, Example 118 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283469BDBM283469(US10023557, Example 121 | N-((6-amino-2-methylpyri...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283468BDBM283468(US10023557, Example 120 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283454BDBM283454(US10023557, Example 107 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283456BDBM283456(US10023557, Example 108 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283459BDBM283459(US10023557, Example 111 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283458BDBM283458(US10023557, Example 110 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283461BDBM283461(US10023557, Example 113 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283460BDBM283460(US10023557, Example 112 | N-((6-amino-2-methylpyri...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283479BDBM283479(US10023557, Example 131 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283478BDBM283478(US10023557, Example 130 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283481BDBM283481(US10023557, Example 133 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283480BDBM283480(US10023557, Example 132 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283484BDBM283484(US10023557, Example 136 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283471BDBM283471(US10023557, Example 123 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283470BDBM283470(US10023557, Example 122 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283473BDBM283473(US10023557, Example 125 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283472BDBM283472(US10023557, Example 124 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283475BDBM283475(US10023557, Example 127 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283474BDBM283474(US10023557, Example 126 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283476BDBM283476(US10023557, Example 128 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 314643BDBM314643(N-((1-aminoisoquinolin-6-yl)methyl)-2-((7- chloroq...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283486BDBM283486(US10023557, Example 138 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283489BDBM283489(US10023557, Example 141 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283488BDBM283488(US10023557, Example 140 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283491BDBM283491(US10023557, Example 143 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283490BDBM283490(US10023557, Example 142 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283493BDBM283493(US10023557, Example 145 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283492BDBM283492(US10023557, Example 144 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283351BDBM283351(US10023557, Example 3 | N-((1-aminoisoquinolin-6-y...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283353BDBM283353(US10023557, Example 5 | N-((3-chloro-6-fluoro-1H-i...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283355BDBM283355(US10023557, Example 7 | N-((6-amino-2,4-dimethylpy...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283354BDBM283354(US10023557, Example 6 | N-((1-aminoisoquinolin-6-y...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283367BDBM283367(US10023557, Example 19 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283366BDBM283366(US10023557, Example 18 | N-((6-fluoro-1H-indol-5-y...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283369BDBM283369(US10023557, Example 21 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283368BDBM283368(US10023557, Example 20 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283360BDBM283360(US10023557, Example 12 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283363BDBM283363(US10023557, Example 15 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283365BDBM283365(US10023557, Example 17 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283364BDBM283364(US10023557, Example 16 | N-((1-aminoisoquinolin-6-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283383BDBM283383(US10023557, Example 35 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283382BDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283385BDBM283385(US10023557, Example 37 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 283382BDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

Displayed 1 to 50 (of 146 total ) | Next | Last >>
Jump to: